We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
FOSAPREPITANT-AFT (AFT Pharmaceuticals Pty Ltd)
Product name
FOSAPREPITANT-AFT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
139 (255 working days)
Active ingredients
Fosaprepitant dimeglumine
Registration type
New generic medicine
Indication
FOSAPREPITANT-AFT, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:
- highly emetogenic cancer chemotherapy (see Section 4.2 Dose and Method of Administration)
- moderately emetogenic cancer chemotherapy (see Section 4.2 Dose and Method of Administration).